AI Article Synopsis
- Sarcoma treatment requires collaboration among specialists due to its rarity and complexity, involving surgical, radiation, and medical management.
- Recent advancements have improved treatment guidelines for systemic therapies in advanced soft tissue sarcoma, thanks to new immunotherapies and targeted therapies.
- The Midwest Sarcoma Trials Partnership (MWSTP) effectively connects large academic centers and local community sites, proposing an online model to enhance access to clinical expertise in treating advanced soft tissue sarcoma.
Article Abstract
The treatment of sarcoma necessitates a collaborative approach, given its rarity and complex management. At a single institution, multidisciplinary teams of specialists determine and execute treatment plans involving surgical, radiation, and medical management. Treatment guidelines for systemic therapies in advanced or nonresectable soft tissue sarcoma have advanced in recent years as new immunotherapies and targeted therapies become available. Collaboration between institutions is necessary to facilitate accrual to clinical trials. Here, we describe the success of the Midwest Sarcoma Trials Partnership (MWSTP) in creating a network encompassing large academic centers and local community sites. We propose a new model utilizing online platforms to expand the reach of clinical expertise for the treatment of advanced soft tissue sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095464 | PMC |
| http://dx.doi.org/10.3390/jcm12072561 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!